Literature DB >> 11402224

An investigation into the pathogenesis of vulvo-vaginal candidosis.

S S El-Din1, M T Reynolds, H R Ashbee, R C Barton, E G Evans.   

Abstract

OBJECTIVE: To monitor yeasts isolated from women during and between episodes of recurrent vulvo-vaginal candidosis (VVC) to determine whether vaginal relapse or re-infection occurred.
METHODS: Women presenting at the genitourinary medicine clinic with signs and symptoms of VVC were recruited to the study (n = 121). A vaginal washing, high vaginal swab (HVS) and rectal swab were taken and the women treated with a single 500 mg clotrimazole pessary. Women were asked to re-attend after 1, 4, and 12 weeks, or when the VVC recurred, when vaginal washings and HVS were repeated. Candida isolates recovered were strain typed using the Ca3 probe and their similarity assessed. Antifungal susceptibility to fluconazole and clotrimazole were determined.
RESULTS: Of the women recruited, 47 completed the study, either returning for four visits or suffering a recurrence during the study period. Of the 22 women who experienced recurrence, the same strain was responsible for the initial and recurrent episode in 17 women. For the remaining five women, four had strain replacement and one had a change of species. None of the isolates recovered from the women demonstrated resistance to either clotrimazole or fluconazole.
CONCLUSIONS: Our findings support the theory of vaginal relapse and thus may support the use of more prolonged courses of antifungal therapy initially to increase the chances of eradication of the yeast.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402224      PMCID: PMC1744307          DOI: 10.1136/sti.77.3.179

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  22 in total

1.  Rapid identification of Candida albicans by filamentation on serum and serum substitutes.

Authors:  C L TASCHDJIAN; J J BURCHALL; P J KOZINN
Journal:  AMA J Dis Child       Date:  1960-02

2.  Application of DNA typing methods to epidemiology and taxonomy of Candida species.

Authors:  S Scherer; D A Stevens
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

3.  Effect of simultaneous oral and vaginal treatment on the rate of cure and relapse in vaginal candidosis.

Authors:  J D Milne; D W Warnock
Journal:  Br J Vener Dis       Date:  1979-10

4.  Co-treatment of the male partner in vaginal candidosis: a double-blind randomized control study.

Authors:  M P Bisschop; J M Merkus; H Scheygrond; J van Cutsem
Journal:  Br J Obstet Gynaecol       Date:  1986-01

5.  Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans.

Authors:  M I O'Connor; J D Sobel
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

6.  Vaginal candidosis: relation between yeast counts and symptoms and clinical signs in non-pregnant women.

Authors:  V Hopwood; T Crowley; C T Horrocks; J D Milne; P K Taylor; D W Warnock
Journal:  Genitourin Med       Date:  1988-10

7.  Demonstration of typical features of individual Candida albicans strains as a means of studying sources of infection.

Authors:  W Meinhof
Journal:  Chemotherapy       Date:  1982       Impact factor: 2.544

8.  Genital candidosis.

Authors:  F C Odds
Journal:  Clin Exp Dermatol       Date:  1982-07       Impact factor: 3.470

9.  Vaginal yeasts in the era of "over the counter" antifungals.

Authors:  P P Walker; M T Reynolds; H R Ashbee; C Brown; E G Evans
Journal:  Sex Transm Infect       Date:  2000-12       Impact factor: 3.519

10.  Treatment of vaginal candidosis with natamycin and effect of treating the partner at the same time.

Authors:  A Buch; E Skytte Christensen
Journal:  Acta Obstet Gynecol Scand       Date:  1982       Impact factor: 3.636

View more
  7 in total

1.  Vulvovaginal candidiasis.

Authors:  D J White; A Vanthuyne
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

2.  Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.

Authors:  E P Garvey; W J Hoekstra; R J Schotzinger; J D Sobel; E A Lilly; P L Fidel
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

3.  Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.

Authors:  Shu-Hua Ge; Zhe Wan; Juan Li; Jianping Xu; Ruo-Yu Li; Feng-Yan Bai
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

4.  Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.

Authors:  Sandra S Richter; Rudolph P Galask; Shawn A Messer; Richard J Hollis; Daniel J Diekema; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

5.  Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.

Authors:  Monika Sojakova; Denisa Liptajova; Miroslav Borovsky; Julius Subik
Journal:  Mycopathologia       Date:  2004-02       Impact factor: 2.574

6.  Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study.

Authors:  D J White; A Vanthuyne; P M Wood; J G Ayres
Journal:  Sex Transm Infect       Date:  2004-06       Impact factor: 3.519

7.  Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test.

Authors:  Agnes Marot-Leblond; Sandrine Nail-Billaud; Françoise Pilon; Bertrand Beucher; Daniel Poulain; Raymond Robert
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.